secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2023-07-10T23:59:59+00:00
Accession:  0001193125-23-184757
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian announces positive Phase 1/2 data for VRDN-001 in chronic TED; THRIVE trial amended
--------------------------------------------------------------------------------

- VRDN-001 showed mean proptosis reduction of 1.6 mm (combined doses) at week 6; proptosis responder rate 42%.
- No serious adverse events, hearing impairment, or hyperglycemia reported in chronic TED patients.
- THRIVE Phase 3 trial amended to 5-dose regimen; topline results expected mid-2024.
- THRIVE-2 Phase 3 in chronic TED to start Q3 2023; topline results expected by year-end 2024.
- IND filed for VRDN-003 and VRDN-001 SC; lead SC candidate selection expected by year-end 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523184757/0001193125-23-184757-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523184757/d440197d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-184757

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer